Malignant Neoplasms
Sanofi Invests €300M in Orano Med for Next-Generation Radioligand Therapies
Sanofi, Orano Med, Radioligand Therapies, Rare Cancers, AlphaMedix, Lead-212 (212Pb), Targeted Alpha Therapies
Ono Pharmaceutical Partners with LigaChem Biosciences for ADC Research and Development
Ono Pharmaceutical, LigaChem Biosciences, Antibody-Drug Conjugate (ADC), LCB97, ConjuAll ADC platform, Solid Tumors, Cancer Treatment
Aptadir Therapeutics Unveils Novel RNA Inhibitors to Combat Cancer and Genetic Disorders
Aptadir Therapeutics, RNA inhibitors, DNMT1 interacting RNAs (DiRs), Cancer treatment, Genetic diseases, Epigenetic targeting, RNA therapeutics
ITM Secures Exclusive Global License for Debiopharm’s CA IX-Targeted Theranostic Pair
ITM, Debiopharm, CA IX, Theranostic Pair, Radiopharmaceutical, Solid Tumors, Cancer Treatment
PanTera Secures €93M to Tackle Alpha-Emitter Isotope Shortage Amid Growing Demand
Alpha-emitters, Isotope shortage, PanTera, Cancer treatment, Radiation therapy
Duality Biotherapeutics Files for Hong Kong IPO, Expanding ADC Therapeutics Portfolio
Duality Biotherapeutics, Hong Kong IPO, ADC Therapeutics, BioNTech, BeiGene, Cancer Treatment
Merck & Co. Expands Oncology Pipeline with Kelun-Biotech ADCs
Merck & Co., Kelun-Biotech, Antibody-Drug Conjugates (ADCs), Cancer Treatment, Oncology Pipeline
Grail Lays Off About 350 Employees, Puts Brakes on New Hires
Grail, layoffs, restructuring, biotech, cancer detection, Galleri test, Illumina, workforce reduction, cost-cutting measures
GSK Secures Another Legal Victory in Latest Zantac Verdict
GSK, Zantac, legal victory, cancer claims, ranitidine, NDMA, FDA, pharmaceutical litigation
IDEAYA Secures $400M Option Deal with Biocytogen for Bispecific ADC
IDEAYA Biosciences, Biocytogen, Bispecific ADC, Option Deal, Cancer Treatment